Celcuity, Inc. (NASDAQ:CELC) Stock Has Consensus Target Price of $152.57 According to Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: Thirteen of 15 analysts rate Celcuity a buy, while two recommend selling. The average 12-month price target is $152.57, well above the stock’s reported $65.80 price.
• Institutional ownership remains significant: Institutional investors and hedge funds own 63.33% of Celcuity, with several major firms recently establishing or expanding positions.
• Shares have declined and earnings missed expectations: CELC trades below its 50-day and 200-day moving averages and recently reported a quarterly loss of $1.44 per share, missing the consensus estimate of a $1.16 loss.

Celcuity, Inc. (NASDAQ:CELC - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the fifteen analysts that are presently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell recommendation and thirteen have given a buy recommendation to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $152.57.

Several analysts have recently issued reports on CELC shares. Guggenheim increased their price objective on Celcuity from $165.00 to $175.00 and gave the company a "buy" rating in a research note on Monday, August 17th. Stifel Nicolaus decreased their target price on Celcuity from $175.00 to $150.00 and set a "buy" rating for the company in a report on Friday, August 14th. Citigroup reissued a "market outperform" rating on shares of Celcuity in a research note on Monday, October 19th. Needham & Company LLC cut their price target on Celcuity from $140.00 to $134.00 and set a "buy" rating on the stock in a report on Wednesday, September 30th. Finally, HC Wainwright restated a "buy" rating and set a $155.00 price target on shares of Celcuity in a report on Friday, August 14th.

Institutional Trading of Celcuity

Hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE purchased a new position in Celcuity in the second quarter worth approximately $153,928,000. Assenagon Asset Management S.A. increased its position in shares of Celcuity by 685.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company's stock valued at $117,579,000 after purchasing an additional 1,290,466 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Celcuity by 111.4% in the 2nd quarter. Wellington Management Group LLP now owns 906,595 shares of the company's stock valued at $94,848,000 after purchasing an additional 477,643 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Celcuity in the 2nd quarter valued at approximately $12,175,000. Finally, Alyeska Investment Group L.P. increased its position in shares of Celcuity by 127.2% in the 2nd quarter. Alyeska Investment Group L.P. now owns 170,846 shares of the company's stock valued at $17,874,000 after purchasing an additional 95,664 shares during the last quarter. Institutional investors and hedge funds own 63.33% of the company's stock.

Celcuity Price Performance

CELC stock opened at $65.80 on Tuesday. The business's fifty day moving average price is $79.55 and its 200 day moving average price is $101.12. Celcuity has a 12-month low of $53.54 and a 12-month high of $151.02. The company has a current ratio of 8.93, a quick ratio of 8.93 and a debt-to-equity ratio of 6.04. The company has a market capitalization of $3.22 billion, a PE ratio of -15.30 and a beta of 0.10.

Celcuity (NASDAQ:CELC - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($1.44) earnings per share for the quarter, missing analysts' consensus estimates of ($1.16) by ($0.28). On average, sell-side analysts anticipate that Celcuity will post -4.98 EPS for the current year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company's CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.